<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03676504</url>
  </required_header>
  <id_info>
    <org_study_id>HD-CAR-1</org_study_id>
    <nct_id>NCT03676504</nct_id>
  </id_info>
  <brief_title>Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR</brief_title>
  <official_title>Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Lymphocytes Transduced by RV-SFG.CD19.CD28.4-1BBzeta Retroviral Vector - a Unicenter Phase I/II Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Heidelberg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Heidelberg</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Adult patients with r/r acute lymphoblastic leukemia (ALL) (stratum I), r/r Non-Hodgkin's&#xD;
      lymphoma (NHL) including chronic lymphocytic leukaemia (CLL), diffuse large B-cell lymphoma&#xD;
      (DLBCL), follicular lymphoma (FL) or mantle cell lymphoma (MCL) (stratum II) as well as&#xD;
      paediatric patients with r/r ALL (stratum III) will be treated with autologous T-lymphocytes&#xD;
      transduced by the third-generation RV-SFG.CD19.CD28.4-1BBzeta retroviral vector. The main&#xD;
      purpose of this study is to evaluate safety and feasibility of escalating CD19.CAR T cell&#xD;
      doses (1-20×20^7 transduced cells/m^2) after lymphodepletion with fludarabine and&#xD;
      cyclophosphamide.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 7, 2018</start_date>
  <completion_date type="Anticipated">October 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of CD19.CAR T cell administration assessing grade and frequency of toxicities including cytokine release syndrome (CRS) and neurotoxicity according to Common Toxicity Criteria for Adverse Events (CTCAE)</measure>
    <time_frame>Up to 90 days after CD19.CAR T cell administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Feasibility of CD19.CAR T cell manufacturing assessing the number of transduced T cells</measure>
    <time_frame>Within 45 days prior to CD19.CAR T cell administration</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Acute Lymphoblastic Leukemia, Adult</condition>
  <condition>Acute Lymphoblastic Leukemia, Pediatric</condition>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <condition>Diffuse Large B Cell Lymphoma</condition>
  <condition>Follicular Lymphoma</condition>
  <condition>Mantle Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Stratum I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adult patients with relapsed or refractory ALL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stratum II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adult patients with relapsed or refractory CLL, DLBCL, FL or MCL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stratum III</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pediatric patients with relapsed or refractory ALL</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CD19.CAR T Cells</intervention_name>
    <description>Dose Level 1: 1×10^6 transduced cells/m^2; Dose Level 2: 5×10^6 transduced cells/m^2; Dose Level 3: 20×10^6 transduced cells/m^2; Dose Level 4: 5x10^7 transduced cells/m^2; Dose Level 5: 10x10^7 transduced cells/m^2; Dose Level 6: 20x10^7 transduced cells/m^2</description>
    <arm_group_label>Stratum I</arm_group_label>
    <arm_group_label>Stratum II</arm_group_label>
    <arm_group_label>Stratum III</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>3 days of fludarabine 30 mg/m^2/day</description>
    <arm_group_label>Stratum I</arm_group_label>
    <arm_group_label>Stratum II</arm_group_label>
    <arm_group_label>Stratum III</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>3 days of cyclophosphamide 500 mg/m^2/day</description>
    <arm_group_label>Stratum I</arm_group_label>
    <arm_group_label>Stratum II</arm_group_label>
    <arm_group_label>Stratum III</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Stratum I/II (Adults):&#xD;
&#xD;
          -  Confirmed CD19+ ALL, CLL, DLBCL, FL or MCL in patients ≥ 18 years&#xD;
&#xD;
          -  ALL (Ph+ and Ph-): Confirmed CD19+ ALL by cytology and flow cytometry (FACS) AND&#xD;
&#xD;
          -  Relapsed or refractory disease (including &quot;molecular relapse&quot; with minimal residual&#xD;
             disease (MRD) levels &gt; 10^-3 at two occasions &gt; 2 weeks apart) with confirmed CD19&#xD;
             expression on malignant cells in relapse&#xD;
&#xD;
               -  Any relapse after allogeneic stem cell transplantation (alloSCT) (≥ 6 months from&#xD;
                  alloSCT at time of CAR T cell infusion) OR&#xD;
&#xD;
               -  Any relapse failing to achieve an MRD level of &lt; 10^-3 after ≥ 2 lines of&#xD;
                  treatment OR&#xD;
&#xD;
               -  Primary refractory as defined by not achieving a complete remission (CR) after ≥&#xD;
                  2 lines of treatment&#xD;
&#xD;
          -  CLL/NHL: Confirmed CD19+ CLL/NHL (including CLL, DLBCL, FL or MCL) with&#xD;
&#xD;
               -  CLL in need of treatment with:&#xD;
&#xD;
                    1. Early relapse (within 2 years) after end of chemoimmunotherapy or&#xD;
                       chemoimmunotherapy refractoriness plus failure or intolerance of both&#xD;
                       Bruton's tyrosine kinase Inhibitor (BTKi) and B-cell lymphoma 2 inhibitors&#xD;
                       (BCL-2i) OR&#xD;
&#xD;
                    2. Relapse after alloSCT, ineligible for or refractory to standard&#xD;
                       interventions (donor lymphocyte infusions (DLI), CD20 antibodies,&#xD;
                       chemoimmunotherapy)&#xD;
&#xD;
               -  DLBCL with:&#xD;
&#xD;
                    1. Refractoriness to a 2nd or later line of chemoimmunotherapy OR&#xD;
&#xD;
                    2. Relapse after autologous stem cell transplantation (autoSCT) plus&#xD;
                       ineligibility for alloSCT (including refractoriness to one line of salvage&#xD;
                       chemoimmunotherapy) OR&#xD;
&#xD;
                    3. Relapse after alloSCT&#xD;
&#xD;
               -  FL in need of treatment with:&#xD;
&#xD;
                    1. Relapse &lt;2 years after chemoimmunotherapy AND ineligibility for or failure&#xD;
                       of autologous stem cell transplantation (autoSCT) AND ineligibility for or&#xD;
                       failure of idelalisib OR&#xD;
&#xD;
                    2. Relapse after alloSCT, ineligible for or refractory to standard&#xD;
                       interventions (DLI, CD20 antibodies, chemoimmunotherapy)&#xD;
&#xD;
               -  MCL with:&#xD;
&#xD;
                    1. Relapse after standard first-line therapy AND ineligibility for or failure&#xD;
                       to BTKi salvage therapy OR&#xD;
&#xD;
                    2. Relapse after alloSCT AND ineligibility for or failure to BTKi salvage&#xD;
                       therapy&#xD;
&#xD;
          -  Measurable disease/MRD at time of enrollment&#xD;
&#xD;
          -  Life expectancy ≥ 12 weeks&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 at the time of&#xD;
             screening&#xD;
&#xD;
          -  Adequate organ function:&#xD;
&#xD;
               -  Renal function defined as: serum creatinine of ≤ 2 x ULN or estimated glomerular&#xD;
                  filtration rate (eGFR) ≥ 30 mL/min/1.73 m^2&#xD;
&#xD;
               -  Liver function defined as:&#xD;
&#xD;
               -  ALT ≤ 5 times the ULN for the respective age&#xD;
&#xD;
               -  Bilirubin ≤ 2.0 mg/dl with the exception of patients with hyperbilirubinemia&#xD;
                  explained by Gilbert-Meulengracht syndrome (may be included if total bilirubin is&#xD;
                  ≤ 3.0 x ULN and direct bilirubin ≤ 1.5 x ULN) or extrahepatic disease (e.g.&#xD;
                  chronic hemolytic anemia)&#xD;
&#xD;
               -  minimum level of pulmonary reserve defined as ≤ grade 1 dyspnea and pulse&#xD;
                  oxygenation &gt; 90% on room air&#xD;
&#xD;
               -  Hemodynamic stability and left ventricular ejection fraction (LVEF) ≥ 40% as&#xD;
                  confirmed by echocardiogram&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) ≥ 500/mm3&#xD;
&#xD;
               -  Absolute lymphocyte count (ALC) ≥ 100/mm3&#xD;
&#xD;
          -  Women of child-bearing potential (defined as all women physiologically capable of&#xD;
             becoming pregnant) and all male participants must agree to use highly effective&#xD;
             methods of contraception for one year following CD19.CAR T cell therapy&#xD;
&#xD;
          -  Ability to understand the nature of the trial and the trial related procedures&#xD;
&#xD;
          -  Written informed consent must be obtained prior to any screening procedures&#xD;
&#xD;
        Stratum III (Children and Adolescents with ALL):&#xD;
&#xD;
          -  Age of &gt; 3 years until &lt; 18 years at the time of screening&#xD;
&#xD;
          -  CD19+ ALL (Ph+ and Ph-) confirmed by cytology and flow cytometry (FACS) AND&#xD;
&#xD;
          -  Relapsed or refractory disease (including &quot;molecular relapse&quot; with polymerase chain&#xD;
             reaction (PCR) MRD &gt; 10^-3 at two occasions &gt; 2 weeks apart) with confirmed CD19&#xD;
             expression on malignant cells in relapse&#xD;
&#xD;
               -  Any relapse after alloSCT (≥ 6 months from alloSCT at time of CAR T cell&#xD;
                  infusion) OR&#xD;
&#xD;
               -  Any relapse failing to achieve an MRD level of &lt; 10^-3 after ≥ 2 lines of&#xD;
                  treatment OR&#xD;
&#xD;
               -  Primary refractory as defined by not achieving a CR after ≥ 2 lines of treatment&#xD;
&#xD;
          -  Measurable disease/MRD at time of enrollment&#xD;
&#xD;
          -  Life expectancy ≥ 12 weeks&#xD;
&#xD;
          -  ECOG performance status ≤ 2 (age ≥ 16 years) or Lansky performance status ≥ 50 (age &lt;&#xD;
             16 years) at the time of screening&#xD;
&#xD;
          -  Adequate organ function:&#xD;
&#xD;
               -  Renal function defined as serum creatinine-clearance ≥ 30 mL/min/1.73 m^2&#xD;
&#xD;
               -  Liver function defined as:&#xD;
&#xD;
               -  ALT ≤ 5 times the ULN for the respective age&#xD;
&#xD;
               -  Bilirubin ≤ 2.0 mg/dl with the exception of patients with hyperbilirubinemia&#xD;
                  explained by Gilbert-Meulengracht syndrome or extrahepatic disease (e.g. chronic&#xD;
                  hemolytic anemia)&#xD;
&#xD;
               -  minimum level of pulmonary reserve defined as ≤ grade 1 dyspnea and pulse&#xD;
                  oxygenation &gt; 90% on room air&#xD;
&#xD;
               -  Hemodynamic stability and LVEF ≥ 40% or shortening fraction &gt; 29% as confirmed by&#xD;
                  echocardiogram&#xD;
&#xD;
               -  ANC) ≥ 500/mm3&#xD;
&#xD;
               -  ALC ≥ 100/mm3&#xD;
&#xD;
          -  Women of child-bearing potential (defined as all women physiologically capable of&#xD;
             becoming pregnant) and postpubertal male participants must agree to use highly&#xD;
             effective methods of contraception for one year following CD19.CAR T cell therapy&#xD;
&#xD;
          -  Written informed consent of the study patient and/or the legal representative must be&#xD;
             obtained prior to any screening procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Stratum I/II (Adults):&#xD;
&#xD;
          -  The following medications are excluded:&#xD;
&#xD;
               -  Immunosuppressive medication with the exception of ≤ 30 mg prednisolone/d or&#xD;
                  equivalent at the time of CAR T cell transfusion&#xD;
&#xD;
               -  Bridging/maintenance therapy including chemo- and immunotherapy must be stopped ≥&#xD;
                  2 weeks prior to leukapheresis, but can be continued between leukapheresis and&#xD;
                  lymphodepletion&#xD;
&#xD;
          -  Intrathecal chemotherapy is possible at any time, but not during lymphodepletion until&#xD;
             14 days after CD19.CAR T cell transfusion&#xD;
&#xD;
          -  Any DLI must be completed &gt; 6 weeks prior to CD19.CAR T cell infusion&#xD;
&#xD;
          -  Florid/acute or chronic Graft-versus-Host disease (GvHD)&#xD;
&#xD;
          -  Uncontrolled active hepatitis B or C&#xD;
&#xD;
          -  HIV-positivity&#xD;
&#xD;
          -  Uncontrolled acute life-threatening bacterial, viral or fungal infection&#xD;
&#xD;
          -  Severe concomitant disease (e.g. uncontrolled arterial hypertension, heart failure New&#xD;
             York Heart Association (NYHA) III-IV, uncontrolled diabetes mellitus, uncontrolled&#xD;
             hyperlipidemia)&#xD;
&#xD;
          -  Unstable angina and/or myocardial infarction within 3 months prior to screening&#xD;
&#xD;
          -  Any previous or concurrent malignancy.&#xD;
&#xD;
        The following exceptions do NOT constitute exclusion criteria:&#xD;
&#xD;
          -  Adequately treated basal cell or squamous cell carcinoma (adequate wound healing is&#xD;
             required prior to study entry)&#xD;
&#xD;
          -  In situ carcinoma of the cervix or breast, treated curatively without evidence of&#xD;
             recurrence ≥ 3 years prior to the study&#xD;
&#xD;
          -  CLL or FL transformed into an aggressive B cell lymphoma&#xD;
&#xD;
          -  A primary malignancy which is in complete remission for ≥ 5 years&#xD;
&#xD;
               -  Pregnant or nursing (lactating) women&#xD;
&#xD;
               -  Intolerance to the excipients of the cell product&#xD;
&#xD;
               -  Active central nervous System (CNS) involvement in ALL patient at the time of&#xD;
                  screening is not an exclusion criterion, but patients with CNS 3 status at&#xD;
                  clinical screening (d-14) are not eligible for CD19.CAR T cell transfusion&#xD;
&#xD;
               -  Participation in another clinical trial at the time of screening&#xD;
&#xD;
        Stratum III (Children and Adolescents with ALL):&#xD;
&#xD;
          -  The following medications are excluded:&#xD;
&#xD;
               -  immunosuppressive medication with the exception of &lt; 0.5 mg/d*kg body weight (BW)&#xD;
                  prednisolone-equivalent at the time of CD19.CAR T cell transfusion&#xD;
&#xD;
               -  Bridging/Maintenance therapy including chemo- and immunotherapy must be stopped ≥&#xD;
                  2 weeks prior to leukapheresis, but can be continued between leukapheresis and&#xD;
                  lymphodepletion&#xD;
&#xD;
          -  Intrathecal chemotherapy is possible at any time, but not during lymphodepletion until&#xD;
             14 days after CD19.CAR T cell transfusion&#xD;
&#xD;
          -  Any DLI must be completed &gt; 6 weeks prior to CD19.CAR T cell infusion&#xD;
&#xD;
          -  Florid/acute or chronic GvHD&#xD;
&#xD;
          -  Uncontrolled active hepatitis B or C&#xD;
&#xD;
          -  HIV-positivity&#xD;
&#xD;
          -  Uncontrolled acute life-threatening bacterial, viral or fungal infection&#xD;
&#xD;
          -  Severe concomitant disease (e.g. any life-limiting genetic disorder). Patients with&#xD;
             Down Syndrome will not be excluded.&#xD;
&#xD;
          -  Any previous or concurrent malignancy.&#xD;
&#xD;
        The following exceptions do not constitute exclusion criteria:&#xD;
&#xD;
          -  Lymphoblastic lymphoma transformed into a CD19+ acute lymphoblastic leukemia&#xD;
&#xD;
          -  A primary malignancy which is in complete remission for ≥ 5 years&#xD;
&#xD;
               -  Pregnant or nursing (lactating) women&#xD;
&#xD;
               -  Intolerance to the excipients of the cell product&#xD;
&#xD;
               -  Active CNS involvement at the time of screening is not an exclusion criterion,&#xD;
                  but patients with CNS 3 status at clinical screening (d-14) are not eligible for&#xD;
                  CD19.CAR T cell transfusion&#xD;
&#xD;
               -  Participation in another clinical trial at the time of screening&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Prof. Dr. Michael Schmitt</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Heidelberg, Department V</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Prof. Dr. Andreas Kulozik</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Heidelberg, University Medical Center for Children and Adolescents</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Prof. Dr. Michael Schmitt</last_name>
    <phone>+49-6221-566614</phone>
    <email>michael.schmitt@med.uni-heidelberg.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prof. Dr. Michael Schmitt</last_name>
      <phone>+49-6221-566614</phone>
      <email>michael.schmitt@med.uni-heidelberg.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prof. Dr. Michael Schmitt</last_name>
      <phone>+49-6221-566614</phone>
      <email>michael.schmitt@med.uni-heidelberg.de</email>
    </contact>
    <investigator>
      <last_name>Prof. Dr. Michael Schmitt</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Prof. Dr. Andreas Kulozik</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>September 7, 2018</study_first_submitted>
  <study_first_submitted_qc>September 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 18, 2018</study_first_posted>
  <last_update_submitted>November 18, 2020</last_update_submitted>
  <last_update_submitted_qc>November 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Heidelberg</investigator_affiliation>
    <investigator_full_name>Prof. Dr. Michael Schmitt</investigator_full_name>
    <investigator_title>Head of the GMP Core Facility University Hospital Heidelberg, Principal Investigator, Clinical Professor for Cellular Immunotherapy</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

